The HABP2 G534E Variant is an Unlikely Cause of Familial Non-medullary Thyroid Cancer
Overview
Authors
Affiliations
Context: A recent study reported the non-synonymous G534E (rs7080536, allele A) variant in the HABP2 gene as causal in familial non-medullary thyroid cancer (NMTC).
Objective: The objective of this study was to evaluate the causality of HABP2 G534E in the TCUKIN study, a multi-center population based study of NMTC cases from the British Isles.
Design And Setting: A case-control analysis of rs7080536 genotypes was performed using 2,105 TCUKIN cases and 5,172 UK controls.
Participants: Cases comprised 2,105 NMTC cases. Patients sub-groups with papillary (N=1,056), follicular (N=691) and Hurthle cell (N=86) TC cases were studied separately. Controls comprised 5,172 individuals from the 1958 Birth Cohort (58C) and the National Blood Donor Service (NBS) study. The controls had previously been genotyped using genome-wide SNP arrays by the Wellcome Trust Case Control Consortium study.
Outcome: Measures: Association between HABP2 G534E (rs7080536A) and NMTC risk was evaluated using logistic regression.
Results: The frequency of HABP2 G534E was 4.2% in cases and 4.6% in controls. We did not detect an association between this variant and NMTC risk (OR=0.896, 95% CI: 0.746-1.071, P=0.233). We also failed to detect an association between HABP2 G534E and cases with papillary (1056 cases, G534E frequency= 3.5%, OR=0.74, P=0.017), follicular (691 cases, G534E frequency= 4.7%, OR=1.00, P=1.000) or Hurthle cell (86 cases, G534E frequency= 6.3%, OR=1.40, P=0.279) histology.
Conclusions: We found that HABP2 G534E is a low-to-moderate frequency variant in the British Isles and failed to detect an association with NMTC risk, independent of histological type. Hence, our study does not implicate HABP2 G534E or a correlated polymorphism in familial NMTC and additional data are required before using this variant in NMTC risk assessment.
Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.
Jiang Y, Xia Y, Han Z, Hu Y, Huang T Front Oncol. 2024; 14:1286426.
PMID: 38571492 PMC: 10987779. DOI: 10.3389/fonc.2024.1286426.
Sanchez-Ares M, Cameselle-Garcia S, Abdulkader-Nallib I, Rodriguez-Carnero G, Beiras-Sarasquete C, Punal-Rodriguez J Front Endocrinol (Lausanne). 2022; 13:829103.
PMID: 35295987 PMC: 8918666. DOI: 10.3389/fendo.2022.829103.
Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T, Charkhchi P, Zahedi A, Akbari M Hered Cancer Clin Pract. 2022; 20(1):9.
PMID: 35255942 PMC: 8900298. DOI: 10.1186/s13053-022-00215-3.
Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J, Singh P, Yin K, Wang J, Bao Y, Wu M Ann Surg Oncol. 2021; 28(11):6590-6600.
PMID: 33660127 DOI: 10.1245/s10434-021-09745-x.
Cirello V, Colombo C, Karapanou O, Pogliaghi G, Persani L, Fugazzola L Front Endocrinol (Lausanne). 2021; 11:589340.
PMID: 33488516 PMC: 7817808. DOI: 10.3389/fendo.2020.589340.